AU2019364415A1 - ALK2 antibodies and methods of use thereof - Google Patents

ALK2 antibodies and methods of use thereof Download PDF

Info

Publication number
AU2019364415A1
AU2019364415A1 AU2019364415A AU2019364415A AU2019364415A1 AU 2019364415 A1 AU2019364415 A1 AU 2019364415A1 AU 2019364415 A AU2019364415 A AU 2019364415A AU 2019364415 A AU2019364415 A AU 2019364415A AU 2019364415 A1 AU2019364415 A1 AU 2019364415A1
Authority
AU
Australia
Prior art keywords
seq
binding fragment
sequence
isolated antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019364415A
Other languages
English (en)
Inventor
Jennifer Lachey
Jasbir S. Seehra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keros Therapeutics Inc
Original Assignee
Keros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keros Therapeutics Inc filed Critical Keros Therapeutics Inc
Publication of AU2019364415A1 publication Critical patent/AU2019364415A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019364415A 2018-10-23 2019-10-23 ALK2 antibodies and methods of use thereof Pending AU2019364415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749463P 2018-10-23 2018-10-23
US62/749,463 2018-10-23
PCT/US2019/057679 WO2020086730A1 (en) 2018-10-23 2019-10-23 Alk2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2019364415A1 true AU2019364415A1 (en) 2021-05-20

Family

ID=70331231

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019364415A Pending AU2019364415A1 (en) 2018-10-23 2019-10-23 ALK2 antibodies and methods of use thereof

Country Status (10)

Country Link
US (2) US12331124B2 (https=)
EP (1) EP3870613A4 (https=)
JP (2) JP7512272B2 (https=)
KR (1) KR102919834B1 (https=)
CN (2) CN113366019B (https=)
AU (1) AU2019364415A1 (https=)
BR (1) BR112021007660A2 (https=)
CA (1) CA3116900A1 (https=)
IL (1) IL282424A (https=)
WO (1) WO2020086730A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870181B1 (en) 2018-10-26 2024-08-14 Keros Therapeutics, Inc. Crystal forms of an alk2 inhibitor
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
KR20220140802A (ko) 2020-02-11 2022-10-18 리제너론 파아마슈티컬스, 인크. 항-acvr1 항체 및 이의 용도
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
US20250282877A1 (en) * 2021-05-11 2025-09-11 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies
US20250034148A1 (en) * 2021-11-02 2025-01-30 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
WO2024092133A1 (en) * 2022-10-27 2024-05-02 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570458C (en) * 2004-06-09 2014-05-20 Technion Research & Development Foundation Ltd. Antibodies for selective apoptosis of cells
CA2662350A1 (en) 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
WO2011116212A2 (en) 2010-03-17 2011-09-22 Oncomed Pharmaceuticals, Inc. Bone morphogenetic protein receptor binding agents and methods of their use
WO2012065059A2 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Treatment of atherosclerosis with bmp-alk3 antagonists
JP6601687B2 (ja) * 2014-03-31 2019-11-06 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
TWI703156B (zh) * 2015-01-30 2020-09-01 學校法人埼玉醫科大學 抗ａｌｋ２抗體
WO2016154572A1 (en) * 2015-03-26 2016-09-29 Vanderbilt University Antibody-mediated neutralizaton of ebolaviruses
WO2020118011A1 (en) 2018-12-06 2020-06-11 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
KR20220140802A (ko) 2020-02-11 2022-10-18 리제너론 파아마슈티컬스, 인크. 항-acvr1 항체 및 이의 용도
WO2021257532A1 (en) 2020-06-16 2021-12-23 Incyte Corporation Alk2 inhibitors for the treatment of anemia
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
WO2022098821A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating lymphopenia
WO2022099166A1 (en) 2020-11-09 2022-05-12 Keros Therapeutics, Inc. Methods of treating cardiovascular-related disease
US20250282877A1 (en) 2021-05-11 2025-09-11 Keros Therapeutics, Inc. Methods of using alk2 and alk3 antibodies

Also Published As

Publication number Publication date
JP2022505585A (ja) 2022-01-14
US20250270333A1 (en) 2025-08-28
CA3116900A1 (en) 2020-04-30
WO2020086730A1 (en) 2020-04-30
EP3870613A1 (en) 2021-09-01
EP3870613A4 (en) 2022-08-03
CN113366019A (zh) 2021-09-07
BR112021007660A2 (pt) 2021-08-03
JP2024114820A (ja) 2024-08-23
CN113366019B (zh) 2024-08-27
IL282424A (en) 2021-06-30
CN118955715A (zh) 2024-11-15
JP7512272B2 (ja) 2024-07-08
KR102919834B1 (ko) 2026-01-30
US12331124B2 (en) 2025-06-17
KR20210088591A (ko) 2021-07-14
US20210253720A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
US12331124B2 (en) ALK2 antibodies and methods of use thereof
US12522646B2 (en) Activin receptor type II chimeras and methods of use thereof
US12440539B2 (en) Methods of using activin receptor type IIB variants
US20230398118A1 (en) Methods of treating cardiovascular-related disease
US20250270287A1 (en) Activin receptor type ii chimeras and methods of use thereof
US20230372390A1 (en) Methods of treating lymphopenia
US20230265162A1 (en) Methods of using activin receptor type iia variants
US20240228583A1 (en) Activin receptor type ii chimeras and methods of use thereof
US20250188148A1 (en) Methods of administering an activin receptor type iib variant
US12458693B2 (en) Methods of treating iron overload with a BMP inhibitor
US20250282877A1 (en) Methods of using alk2 and alk3 antibodies
HK40119616A (zh) Alk2抗体及其使用方法
HK40089125A (zh) 激活素受体ii型嵌合体以及其使用方法
US20110311532A1 (en) Inhibition of complement and cellular activation